At Extreme Investor Network, we are constantly on the lookout for the latest investing opportunities to help our readers maximize their returns. With the second half of the year in full swing, Oppenheimer has identified its top small- and midcap seasonal standout investment ideas, and we want to share them with you.
Smallcap stocks have had a rough year so far, with the Russell 2000 barely moving up while the S&P 500 has seen significant gains. Midcaps haven’t fared much better, with the S&P 400 MidCap only up 3.8% in 2024. This is where Oppenheimer’s expert analysis comes in, highlighting midcap growth stocks as its top rotation idea based on price charts alone.
Oppenheimer has selected 25 “smidcap” stocks with market capitalizations between $1 billion and $10 billion, all rated as outperform by the investment bank. These stocks cover a range of high-growth themes including artificial intelligence, obesity drugs, online sports betting, and pet humanization.
One standout in the AI space is Zeta Global Holdings, which has seen a remarkable 92% increase in year-to-date returns. Oppenheimer believes there is even more upside potential for the stock, with a $20 price target implying an 18% increase from current levels. Zeta is well-positioned to capitalize on the next generation of marketing automation and benefit from positive secular trends in customer data regulations and the AI investment cycle.
In the healthcare sector, Oppenheimer is bullish on Viking Therapeutics, a player in the fight against obesity. With a price target of $138, implying a 155% upside from current prices, Viking has already tripled in value this year. The company’s GLP-1 and GIP dual agonists VK2735 show promise in the obesity market, making it a potential market leader in the future.
For those interested in the pet industry, Oppenheimer’s top pick is Freshpet, a maker of high-quality pet food and treats. With a market cap of $7.6 billion and a 49% increase in value year-to-date, Freshpet is seen as a long-term growth story in the consumer packaged smallcap sector. Oppenheimer has set a price target of $155 on the stock, signaling a 20% potential upside.
At Extreme Investor Network, we aim to provide our readers with exclusive insights and investment opportunities that can set them apart in the market. Trust our expertise and stay ahead of the curve with our latest recommendations and analysis.